| Followers | 28 |
| Posts | 21628 |
| Boards Moderated | 0 |
| Alias Born | 01/16/2026 |
Monday, February 23, 2026 4:20:58 PM
Gilead Sciences to Present at Upcoming Investor Conferences
February 23, 2026 4:05 PM
Business Wire
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:
-
TD Cowen Annual Health Care Conference on Tuesday, March 3 at 11:10 AM Eastern Time
-
Leerink Partners Global Healthcare Conference on Tuesday, March 10 at 11:20 AM Eastern Time
-
Barclays Annual Global Healthcare Conference on Wednesday, March 11 at 11:00 AM Eastern Time
The live webcasts can be accessed at the company’s investors page at investors.gilead.com. The replays will be available for at least 30 days following the presentation.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter ( @Georgia Bard-GILEAD-5 or 1-650-574-3000.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260223506818/en/
Jacquie Ross, CFA – Investors
investor_relations@gilead.com
Original: Gilead Sciences to Present at Upcoming Investor Conferences
Recent GILD News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/28/2026 12:55:23 AM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 05/28/2026 12:51:00 AM
- Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar) • Business Wire • 05/27/2026 06:00:00 AM
- FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV) • Business Wire • 05/22/2026 06:00:00 PM
- Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors • Business Wire • 05/22/2026 11:47:00 AM
- New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology • Business Wire • 05/21/2026 09:00:00 PM
- Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio • Business Wire • 05/21/2026 01:30:00 PM
- Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease • Business Wire • 05/21/2026 07:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:15:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2026 09:50:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2026 09:45:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 08:15:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/15/2026 08:09:08 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/15/2026 08:07:18 PM
- Gilead Prices $3 Billion of Senior Unsecured Notes • Business Wire • 05/15/2026 01:21:00 AM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 05/14/2026 09:11:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/14/2026 12:46:00 PM
- Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026 • Business Wire • 05/13/2026 12:30:00 PM
- Form 13F-HR - Quarterly report filed by institutional managers, Holdings • Edgar (US Regulatory) • 05/08/2026 09:00:48 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/07/2026 09:13:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 09:12:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 08:03:01 PM
- Gilead Sciences Announces First Quarter Financial Results • Business Wire • 05/07/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/04/2026 08:40:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/04/2026 08:36:45 PM
